Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this
study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

T cells in the immune system protect the human body from infection by pathogens and clear
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …

Chimeric antigen receptor-modified T (CAR-T) cells have achieved significant success in the
treatment of several hematological malignancies. However, the translation of the existing …

The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …

C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia
(AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti …

The development and regulatory approval of chimeric antigen receptor T cell (CAR-T)
therapies targeting the B-lineage surface antigen CD19 represents a major milestone in …